Figure 1.

Tumor-associated pDCs are tolerogenic towards stimulation with TLR7 agonist. (A) Representative dot plots showing TA-pDCs infiltrating various solid tumor types as detected by CD123⁺CD303⁺ staining in single cell suspensions from tumor digests using flow cytometry. (B) Quantification of TA-pDCs (defined as Lin^-CD123⁺CD303⁺ cells) as fraction of living cells in various tumor indications (breast cancer: n=8; colon cancer: n=3; lung cancer: n=4; head and neck cancer: n=5; ovarian cancer: n=4). (C) Quantification of IFN-ɑ release from TLR7-stimulated (left) single cell suspension from breast cancer tissue (n=3) and blood pDCs (right) from healthy donors (n=6). Results are shown as mean ± SEM. See also Supplementary Table S1 .